pages

The Blueteq High Cost Drugs (HCD) system will allow health boards to monitor the prescribing of high-cost medicines and manage the ever-increasing complexities associated with their use. Documents and a list of FAQs are available from this page.

Our committees need lay members to represent the general public and be the voice of patients and carers in Wales. This page tells you more about the role of a lay member, what's involved and how you can get in touch with us to find out more.

Recommendations are moved to the static list when, after AWTTC review, it is clear that no new evidence is likely to be published that would have any material effect on the current advice. Recommendations placed on the static list may be transferred back to the list for further appraisal if new evidence becomes available that is likely to have a material effect on the recommendation issued.